Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMT NASDAQ:AKCA NASDAQ:ARVN NASDAQ:LGND NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$9.21+0.5%$8.35$5.90▼$29.61$672.51M2.392.55 million shs3.46 million shsLGNDLigand Pharmaceuticals$186.98+0.9%$171.07$93.58▼$189.60$3.63B0.95138,999 shs57,931 shsSDGRSchrodinger$22.52+2.6%$19.84$16.60▼$28.47$1.62B1.741.25 million shs1.34 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%AKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas-1.61%-5.37%+21.65%+16.84%-65.46%LGNDLigand Pharmaceuticals-0.17%+2.48%+8.56%+36.38%+73.31%SDGRSchrodinger+5.63%+8.12%+15.22%-1.21%+21.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$9.21+0.5%$8.35$5.90▼$29.61$672.51M2.392.55 million shs3.46 million shsLGNDLigand Pharmaceuticals$186.98+0.9%$171.07$93.58▼$189.60$3.63B0.95138,999 shs57,931 shsSDGRSchrodinger$22.52+2.6%$19.84$16.60▼$28.47$1.62B1.741.25 million shs1.34 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%AKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas-1.61%-5.37%+21.65%+16.84%-65.46%LGNDLigand Pharmaceuticals-0.17%+2.48%+8.56%+36.38%+73.31%SDGRSchrodinger+5.63%+8.12%+15.22%-1.21%+21.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune Therapeutics 0.00N/AN/AN/AAKCAAkcea Therapeutics 0.00N/AN/AN/AARVNArvinas 2.43Hold$16.1875.72% UpsideLGNDLigand Pharmaceuticals 2.71Moderate Buy$176.50-5.60% DownsideSDGRSchrodinger 2.38Hold$26.2916.72% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, LGND, AKCA, SDGR, and AIMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/15/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$8.00 ➝ $6.0010/15/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$8.00 ➝ $6.0010/14/2025SDGRSchrodingerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $28.0010/7/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$16.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$19.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/27/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14ARVNArvinas$263.40M2.57N/AN/A$8.17 per share1.13LGNDLigand Pharmaceuticals$167.13M21.93$1.62 per share115.29$43.95 per share4.25SDGRSchrodinger$207.54M7.99N/AN/A$5.78 per share3.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A50.40N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/5/2025 (Estimated)Latest ARVN, LGND, AKCA, SDGR, and AIMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025LGNDLigand Pharmaceuticals$1.96N/AN/AN/A$58.71 millionN/A11/5/2025Q3 2025SDGRSchrodinger-$0.72N/AN/AN/A$50.51 millionN/A10/29/2025Q3 2025ARVNArvinas-$0.74N/AN/AN/A$29.36 millionN/A8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40AKCAAkcea TherapeuticsN/A12.1711.78ARVNArvinasN/A5.645.64LGNDLigand PharmaceuticalsN/A5.455.21SDGRSchrodingerN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%AKCAAkcea Therapeutics19.27%ARVNArvinas95.19%LGNDLigand Pharmaceuticals91.28%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%AKCAAkcea Therapeutics1.50%ARVNArvinas4.73%LGNDLigand Pharmaceuticals7.00%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableARVNArvinas42073.42 million69.95 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableARVN, LGND, AKCA, SDGR, and AIMT HeadlinesRecent News About These CompaniesSchrödinger to Announce Third Quarter 2025 Financial Results on November 5October 22 at 4:38 PM | theglobeandmail.comARK Investment Management LLC Sells 335,258 Shares of Schrodinger, Inc. $SDGROctober 22 at 9:12 AM | marketbeat.comStephens Investment Management Group LLC Grows Stock Holdings in Schrodinger, Inc. $SDGROctober 22 at 9:12 AM | marketbeat.comSchrödinger to Announce Third Quarter 2025 Financial Results on November 5October 22 at 9:03 AM | businesswire.comStrength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength?October 21 at 8:06 AM | zacks.comAllspring Global Investments Holdings LLC Boosts Stock Position in Schrodinger, Inc. $SDGROctober 21 at 3:25 AM | marketbeat.comSchrodinger (NASDAQ:SDGR) Shares Up 11.3% - Still a Buy?October 20, 2025 | marketbeat.comReviewing Privia Health Group (NASDAQ:PRVA) and Schrodinger (NASDAQ:SDGR)October 20, 2025 | americanbankingnews.comInsider Selling: Schrodinger (NASDAQ:SDGR) Insider Sells 1,395 Shares of StockOctober 18, 2025 | marketbeat.comMargaret Dugan Sells 1,395 Shares of Schrodinger (NASDAQ:SDGR) StockOctober 18, 2025 | insidertrades.comWeiss Ratings Reaffirms "Sell (E+)" Rating for Schrodinger (NASDAQ:SDGR)October 16, 2025 | americanbankingnews.comSchrodinger (NASDAQ:SDGR) Receives Sell (E+) Rating from Weiss RatingsOctober 14, 2025 | marketbeat.comKeybanc Maintains Schrödinger (SDGR) Overweight RecommendationOctober 9, 2025 | msn.comSchrodinger (NASDAQ:SDGR) Price Target Lowered to $28.00 at KeyCorpOctober 8, 2025 | marketbeat.comSlow Capital Inc. Purchases New Shares in Schrodinger, Inc. $SDGROctober 7, 2025 | marketbeat.comCraig-Hallum Keeps Their Buy Rating on Schrodinger (SDGR)October 4, 2025 | theglobeandmail.comSchrodinger (NASDAQ:SDGR) Downgraded to "Sell" Rating by Wall Street ZenOctober 4, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Hold" by AnalystsOctober 4, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Trading Down 3.6% - Here's WhyOctober 3, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Schrödinger (SDGR) with Neutral RecommendationOctober 1, 2025 | msn.comSchrodinger (NASDAQ:SDGR) Stock Rating Upgraded by The Goldman Sachs GroupOctober 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, LGND, AKCA, SDGR, and AIMT Company DescriptionsAimmune Therapeutics NASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Akcea Therapeutics NASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Arvinas NASDAQ:ARVN$9.21 +0.05 (+0.55%) Closing price 04:00 PM EasternExtended Trading$9.32 +0.11 (+1.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Ligand Pharmaceuticals NASDAQ:LGND$186.98 +1.73 (+0.93%) Closing price 04:00 PM EasternExtended Trading$186.99 +0.01 (+0.01%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Schrodinger NASDAQ:SDGR$22.52 +0.56 (+2.55%) Closing price 04:00 PM EasternExtended Trading$22.68 +0.16 (+0.71%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
